75370-65-9

Usage

Uses

Used in Pharmaceutical Industry:
2H-Benzimidazol-2-one,4-amino-1,3-dihydro-(9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its potential medicinal properties. Its unique structure allows it to be a building block in the creation of new drugs that can address a range of health conditions.
Used in Organic Synthesis:
In the field of organic chemistry, 2H-Benzimidazol-2-one,4-amino-1,3-dihydro-(9CI) is utilized as a versatile intermediate for the production of other organic compounds. Its heterocyclic nature makes it a suitable candidate for further chemical reactions and modifications, contributing to the development of novel chemical entities with specific applications.

Upstream product

• 85330-50-3 4-nitro-1H-benzo[d]imidazole-2(3H)-one 
• 606-22-4 2,6-dinitroaniline 
• 606-21-3 1-chloro-2,6-dinitrobenzene 
• 118-97-8 4-chloro-3,5-dinitrobenzoic acid 
• 608-32-2 1,2,3-triaminobenzene 
• 530-62-1 1,1'-carbonyldiimidazole 
• 3694-52-8 2,3-diamino-nitrobenzene 

Downstream Products

• 218933-35-8 4-(4-benzylpiperazin-1-yl)-1,3-dihydro-benzoimidazol-2-one 
• 1338064-94-0 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)acetamide 
• 1338064-47-3 1-(4-chlorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-46-2 1-(4-fluorobenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-55-3 1-(4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-53-1 1-(4-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-52-0 1-(4-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-38-2 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338065-10-3 1-[(4-tert-butylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 
• 1338064-60-0 1-(4-chloro-2-(3-hydroxypyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-39-3 1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-57-5 1-(4-methyl-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-56-4 1-(2-(dimethylamino)-4-methylbenzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 
• 1338064-50-8 1-(4-chloro-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 

Relevant academic research and scientific papers

Preparation method of 4-amino-1, 3-dihydro-benzimidazole-2-one

The invention provides a preparation method of 4-amino-1, 3-dihydro-benzimidazole-2-one, which comprises the following steps: Q1, preparation of 2, 6-dinitrochlorobenzene, Q2, preparation of 2, 6-dinitroaniline, Q3, preparation of 3-nitro-o-phenylenediamine, Q4, preparation of 4-nitro-1H-benzo[d]imidazole-2(3H)-one and Q5, preparation of 4-amino-1, 3-dihydro-benzimidazole-2-one. According to the preparation method, 3, 5-dinitro-4-chlorobenzoic acid which is low in price is used as a raw material, and the high-yield 4-amino-1, 3-dihydro-benzimidazole-2-one is obtained through reactions such asdecarboxylation and ammoniation. The whole reaction process is easy to control, the product yield is high, good social benefits and economic benefits can be brought, and the economic value potential is large.

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

IL-8 receptor antagonists

This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ and NAP-2 mediated diseases.

New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phneylpiperazine dopaminergic template

The synthesis of several bioisoteric analogs based on the 3-OH-N1- phenylpiperazine dopamine D2 agonist template (i.e., 4) is described. The indolone (5) and 2-CF3-benzimidazole (13) were observed to have excellent affinity for the D2 receptor. Several D4 selective compounds were also identified. Molecular modeling studies and a putative bioactive conformation are discussed.